Covered recipient · General Payments record
MARK CHRISTOPHER NADAUD
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2019–2024
$568.34
- Reported across 30 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $296.79 | 10 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $131.71 | 3 |
| MIMEDX Group, Inc. | $43.38 | 1 |
| Novo Nordisk AS | $41.30 | 2 |
| Abbott Laboratories | $39.98 | 2 |
| Amgen Inc. | $20.63 | 1 |
| PFIZER INC. | $19.79 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (10)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $20.58 | 04/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124998204 | CMS |
| Abbott Laboratories | $19.40 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124998206 | CMS |
| Amgen Inc. | $20.63 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111658969 | CMS |
| AstraZeneca Pharmaceuticals LP | $100.41 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105878027 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.88 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104559958 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.42 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104271967 | CMS |
| MIMEDX Group, Inc. | $43.38 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1140265601 | CMS |
| Novo Nordisk Inc | $18.17 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097177810 | CMS |
| Novo Nordisk Inc | $23.13 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097648696 | CMS |
| PFIZER INC. | $19.79 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131228420 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.